Nectar Lifescience's Q2 FY 2025-26 Quarterly Results
- 16 Nov 2025
Result Summary
- Nectar Lifescience Ltd reported a 98.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 98.7%.
- Its expenses for the quarter were down by 98.3% QoQ and 98.5% YoY.
- The net profit increased 178.4% QoQ and decreased 3243.0% YoY.
- The earnings per share (EPS) of Nectar Lifescience Ltd declined at 7.84 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
| (₹ crores) | Q2FY26 | Q1FY26 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 5.74 | 281.02 | 428.79 | -98.0% | -98.7% |
Total Expenses | 6.24 | 377.78 | 420.12 | -98.3% | -98.5% |
Profit Before Tax | -0.51 | -96.75 | 8.67 | -99.5% | -105.9% |
Tax | -0.18 | -33.52 | 3.07 | -99.5% | -105.9% |
Profit After Tax | -176.01 | -63.23 | 5.60 | 178.4% | -3243.0% |
Earnings Per Share | -7.84 | -2.82 | 0.25 | 178.0% | -3236.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nectar Lifescience Ltd is a company that operates within the pharmaceutical and lifesciences sector. It is primarily involved in the manufacturing and marketing of pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, and herbal derivatives. The company is known for its capabilities in producing a wide range of pharmaceutical ingredients and has a presence in both domestic and international markets. While specific recent developments regarding the company are not available in the data provided, Nectar Lifescience Ltd has traditionally focused on expanding its product portfolio and enhancing its manufacturing capabilities to meet global standards.
Revenue
In Q2FY26, Nectar Lifescience Ltd reported a total income of ₹5.74 crores. This reflects a drastic decrease of 98.0% quarter-over-quarter (QoQ) compared to the ₹281.02 crores reported in Q1FY26. Year-over-year (YoY), the total income decreased by 98.7% from ₹428.79 crores in Q2FY25. This significant reduction in total income is a notable factor in the company's financial performance for the quarter. The decrease in revenue may be attributed to various factors not detailed in the provided data, such as market conditions or operational challenges.
Profitability
The profitability metrics for Nectar Lifescience Ltd in Q2FY26 reveal a substantial decline. The company recorded a loss before tax of ₹0.51 crores, compared to a loss of ₹96.75 crores in the previous quarter, Q1FY26, representing a 99.5% decline QoQ. On a YoY basis, this is a decrease from a profit before tax of ₹8.67 crores in Q2FY25, marking a 105.9% decline. The tax expense also showed a decrease, with a negative value of ₹0.18 crores, down from ₹-33.52 crores in Q1FY26 and from ₹3.07 crores in Q2FY25, both representing a 99.5% decline QoQ and 105.9% YoY, respectively. The profit after tax plummeted to a negative ₹176.01 crores in Q2FY26 from a negative ₹63.23 crores in Q1FY26 and ₹5.60 crores in Q2FY25, reflecting a 178.4% increase in losses QoQ and a 3243.0% decline YoY.
Operating Metrics
The earnings per share (EPS) for Nectar Lifescience Ltd in Q2FY26 was a negative ₹7.84, an increase in the loss from a negative ₹2.82 in Q1FY26. YoY, EPS decreased dramatically from ₹0.25 in Q2FY25, representing a 3236.0% decline. This negative EPS indicates a considerable reduction in shareholder earnings compared to previous periods. The total expenses for the quarter were ₹6.24 crores, showing a significant decrease of 98.3% QoQ from ₹377.78 crores in Q1FY26 and a 98.5% decline YoY from ₹420.12 crores in Q2FY25. This reduction in expenses, while substantial, was not sufficient to offset the decline in income, leading to the reported losses for the quarter.
FAQs
When was Nectar Lifescience Ltd Q2 FY 2025-26 result announced?
Nectar Lifescience Ltd announced its Q2 FY 2025-26 results on 16 November, 2025.
What are Nectar Lifescience Ltd quarterly results?
Nectar Lifescience Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Nectar Lifescience Ltd Q2 FY 2025-26 results?
Key highlights of Nectar Lifescience Ltd Q2 FY 2025-26 results include:
- Revenue: ₹5.74 crore
- Net Profit: ₹-176.01 crore
- EBITDA: ₹-175.98 crore
- Year-over-Year Growth: -98.7%
- Quarter-over-Quarter Growth: -98.0%
How did Nectar Lifescience Ltd net profit perform in this quarter?
Nectar Lifescience Ltd reported a net profit of ₹-176.01 crore in Q2 FY 2025-26, reflecting a -3243.0% year-over-year growth.
What was Nectar Lifescience Ltd revenue in Q2 FY 2025-26?
Nectar Lifescience Ltd posted a revenue of ₹5.74 crore in Q2 FY 2025-26.